Optiscan Imaging Limited · ASX:OIL
Optiscan Imaging — Investor Presentation (April 2019)
17 slides from Optiscan Imaging's investor presentation, Apr 29, 2019
Slide 1: Optiscan Imaging Ltd: Unlocking the Potential in Human Applications
Optiscan Imaging Ltd (ASX:OIL) OptisScan Unlocking the Potential in Human Applications Diagnostic and Intraoperative Clinical Devices
Slide 2: Notice
Notice For personal use only This presentation contains forward‐looking and unaudited information. Any forward-looking statements, opinions or estimates in this presentation, including but not limited in relation to any financial or other projections, guidance on future operations or strategies, gro
Slide 3: Global leader in handheld confocal laser microscopy
For personal use only Global leader in handheld confocal laser microscopy Confocal Launched second generation system with smaller Endomicroscopic probe diameter, faster scanning and higher resolution Imaging Technology Developing oral, cervical, oesophageal and breast For medical, translational and
Slide 4: Where we are today
Where we are today For personal use only Current work Future vision Pre-clinical & Brain New Cancer Applications Translational Cancer Research Breast • Product re-branded FIVE2 • Collaboration with (ViewnVivo) Carl Zeiss Meditec Oral • Multiple trial • FDA510(k) and CE demonstrations & funding Mark
Slide 5: Highlights: Progress on our vision
Highlights : Progress on our vision For personal use only “Developer of In-Human Diagnostic and Intraoperative Clinical Devices in Cancer” 1 2 3 Working with Progressed to Seeking FDA 510(k) Memorial Sloan Kettering Stage 2 of Breast Cancer Clearance and Other Cancer Centre (MSKCC)1 Research Trial a
Slide 6: Combination of PARPi-FL agent & Optiscan FIVE2C
1 Combination of PARPi-FL agent & Optiscan FIVE2C For personal use only PARPi-FL Optiscan’s FIVE2C A molecular based optical imaging agent targeting Unique capability for in vivo microscopic imaging, PARP1 which is an enzyme that is highly overexpressed providing instantaneous in vivo examination of
Slide 7: Improving global practice with FIVE2C
1 Improving global practice with FIVE2C For personal use only For many cancers, early detection FIVE2C can address this world-wide 1 requires regular reviews and problem by delivering a microscopic biopsies approach (which can augment the traditional macroscopic approach) in Current global practice
Slide 8: FIVE2 application with MSKCC
1 FIVE2 application with MSKCC For personal use only August Nov Feb Feb Apr Apr Apr 2018 2018 2019 2019 2019 2019 2019 Proof of FIVE2 Collaboration MSKCC working MSKCC began MSKCC initial ex- Visit by MSKCC surgeon concept provided to agreement with with FIVE2 investigational vivo analysis & researc
Slide 9: Scale of Oral, Oesophageal and Cervical Cancer
1 Scale of Oral, Oesophageal and Cervical Cancer For personal use only Oral Cavity, Lip & Oesophageal Cancer Gynaecological Cancer Pharyngeal Cancer 53,000 17,650 13,170 Estimated new cases in the USA Estimated new cases in the USA Estimated new cases in the USA each year1 each year1 each year1 48,1
Slide 10: Breast cancer is the most common cancer in women
2 Breast cancer is the most common cancer in women For personal use only 2.1 15% 556 145 Million of cases centers hospitals 2.1 million new 15% of all new There are 556 Breast There are 145 cases of breast cancer cases in the Centers in the USA hospitals in Australia cancer predicted in United State
Slide 11: Stage of the Breast Cancer Surgical Margin Assessment Trial
For personal use only 2 Stage 2 of the Breast Cancer Surgical Margin Assessment Trial conducted at Matching CLE and H&E – Cancer cells throughout Hollywood Private Hospital Underway with multiple specimens from 5 mastectomy patients with PARPi-FL matching histopathology Matching CLE and H&E – Cluste
Slide 12: Progress to date on Breast Cancer Trial
2 Progress to date on Breast Cancer Trial For personal use only Today Stage 1 Stage 2 Stage 3 Stage 4 October 2018 March 2019 TBC TBC Examination of ex Examination of ex Examination of ex vivo Examination of breast vivo excised breast vivo fresh breast fresh breast tissue tissue in vivo during tissu
Slide 13: Optiscan is seeking regulatory clearances
3 Optiscan is For personal use only • An internal assessment of the Seeking: required technical and regulatory tasks for FDA 510(k) clearance has • 510(k) clearance (USA) been undertaken • CE Mark (Europe) • Discussions are currently taking place with a number of regulatory • TGA approval (Australia
Slide 14: Modifications underway to meet strategic & regulatory needs
Modifications underway to meet strategic & regulatory needs For personal use only Product changes are underway to enable the use of a modified FIVE2 (ViewnVivo) system (FIVE2C), in the: • Proposed MSKCC Oral and Cervical Cancer trials • Breast Cancer Surgical Margin Trial The design and manufacturin
Slide 15: Key takeaways
Key takeaways For personal use only 1 2 3 4 Working with Developing Completing product Seeking global MSKCC and SBI on relationships, modifications to certifications in novel tools for planning and meet expected the USA (510(k)), cancer screening, approvals for strategic in Europe (CE diagnosis and
Slide 16: Appendix: Further technical detail
For personal use only Appendix Further technical detail
Slide 17: PARPi-FL – Optical molecular cancer imaging agent
PARPi-FL – Optical molecular cancer imaging agent For personal use only • A molecular based imaging agent • Has unique pharmacokinetics properties for topical & intravenous use • Targets PARP1, an enzyme that is highly overexpressed in several human cancers such as oral cancer, cervical cancer, brea
Optiscan Imaging — Investor Presentation (April 2019) on 6ix